Three Healthcare Stocks With Great Potential

Stocks all over the board are moving higher as we are now in the fifth year of this strong upward pattern that began in the spring of 2009. This is a theme for most stocks, as is common in a bull market, but there are also stocks that have been a bit slow to get picked up by investors. After doing research for a new opening in my portfolio, I’ve come down to three healthcare stocks that I see great potential in.

• Infinity Pharmaceuticals (INFI) is a drug discovery and development company that focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need.Infinity is developing IPI-145 and IPI-443, potent, oral inhibitors of Class I phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.IPI-145, Infinity’s lead product candidate, is currently progressing in a Phase 1 study in people with advanced hematologic malignancies. Some have noted that IPI-145 holds promise of delivering a multi-billion dollar blockbuster drug.

• EasyMed Services (EMYSF) is a Swiss-based global medical information technology company, founded in 2005, with offices in Geneva, Vancouver and Chennai. EasyMed delivers an end-to-end patient care solution through mobile and smartphone applications for the healthcare, insurance and pharmaceutical industries. An analyst target of $4 can be found on the shares.

• Vivus (VVUS) engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. The company offers Qsymia, a drug for the treatment of obesity and Stendriafor the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea and Qsymia for the treatment of type-2 diabetes.